TrialBlood2022

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.

Moshe Mittelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.